Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model
Background: To investigate the neuroprotective effects of topically applied brimonidine tartrate 0.2% (BMD), an α2‐receptor agonist, on the retinal ganglion cell (RGC) layer and inner nuclear layer (INL) of rabbit retina in endothelin‐1 (ET‐1)‐induced optic nerve (ON) ischaemia model. Methods: Osm...
Gespeichert in:
| Veröffentlicht in: | Clinical & experimental ophthalmology 2007-08, Vol.35 (6), p.527-534 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 534 |
|---|---|
| container_issue | 6 |
| container_start_page | 527 |
| container_title | Clinical & experimental ophthalmology |
| container_volume | 35 |
| creator | Aktas, Zeynep Gurelik, Gokhan Akyurek, Nalan Onol, Merih Hasanreisoglu, Berati |
| description | Background: To investigate the neuroprotective effects of topically applied brimonidine tartrate 0.2% (BMD), an α2‐receptor agonist, on the retinal ganglion cell (RGC) layer and inner nuclear layer (INL) of rabbit retina in endothelin‐1 (ET‐1)‐induced optic nerve (ON) ischaemia model.
Methods: Osmotic minipumps were surgically implanted into one eye of 16 New Zealand Albino rabbits to deliver ET‐1 at the constant rate of 0.5 μL/h for 2 weeks. Eyes were divided into four groups. ET‐1 was given with (Group 3) and without topical BMD therapy (Group 1). Groups 2 and 4 were taken as controls. Rabbits were sacrificed at day 14. Morphological alterations, total cell number and proportion of cells undergoing apoptosis in INL and RGC layer were assessed by histopathological analysis to determine the survival of the cells of the INL and RGC layer.
Results: Endothelin‐1 led to severe reduction of cells in both the RGC layer and INL in Group 1 (P |
| doi_str_mv | 10.1111/j.1442-9071.2007.01533.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20927499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20927499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5023-5b91d778e11b74dc74d2ac71fd0fbab8db799ff8e60ed49f337eb2c73908b3d93</originalsourceid><addsrcrecordid>eNqNkEtv1DAUhSMEog_4C8gb2CX4kcTxggUaSnlU7QZU1I3l2NeqhyQOtkNn_j0OMypbLFk-ks937HuKAhFckbzebitS17QUmJOKYswrTBrGqt2T4vTx4ulRtzWuT4qzGLcY44ay9nlxQjhvccvq02J_DUvwc_AJdHK_AYG1WSFvUfKz02oY9kjN8-DAoD640U_OuAlQUiEFlQDhir5GbkIwGZ_uYXBTSUo3mUVnws_JaTRByMku6nsFo1No9AaGF8Uzq4YIL4_nefH948W3zafy6uby8-b9VakbTFnZ9IIYzjsgpOe10XlTpTmxBtte9Z3puRDWdtBiMLWwjHHoqeZM4K5nRrDz4s0hNw_5a4GY5Jh_AsOgJvBLlBQLymuxGruDUQcfYwAr5zyvCntJsFxrl1u5NirXduVau_xbu9xl9NXxjaUfwfwDjz1nw7uD4cENsP_vYLm5uFlV5ssD72KC3SOvwk_ZcsYbeXt9KTcf8N3dl68_5C37A2mDokw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20927499</pqid></control><display><type>article</type><title>Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Aktas, Zeynep ; Gurelik, Gokhan ; Akyurek, Nalan ; Onol, Merih ; Hasanreisoglu, Berati</creator><creatorcontrib>Aktas, Zeynep ; Gurelik, Gokhan ; Akyurek, Nalan ; Onol, Merih ; Hasanreisoglu, Berati</creatorcontrib><description>Background: To investigate the neuroprotective effects of topically applied brimonidine tartrate 0.2% (BMD), an α2‐receptor agonist, on the retinal ganglion cell (RGC) layer and inner nuclear layer (INL) of rabbit retina in endothelin‐1 (ET‐1)‐induced optic nerve (ON) ischaemia model.
Methods: Osmotic minipumps were surgically implanted into one eye of 16 New Zealand Albino rabbits to deliver ET‐1 at the constant rate of 0.5 μL/h for 2 weeks. Eyes were divided into four groups. ET‐1 was given with (Group 3) and without topical BMD therapy (Group 1). Groups 2 and 4 were taken as controls. Rabbits were sacrificed at day 14. Morphological alterations, total cell number and proportion of cells undergoing apoptosis in INL and RGC layer were assessed by histopathological analysis to determine the survival of the cells of the INL and RGC layer.
Results: Endothelin‐1 led to severe reduction of cells in both the RGC layer and INL in Group 1 (P < 0.05). In Group 3, the total cell number and the proportion of cells undergoing apoptosis in the RGC layer were comparable with the control group (Group 4), whereas the former was found to be higher and the latter was found to be lower than those recorded for Group 1. However, the total cell number in the INL was found to be lower in Group 3 compared with that of Group 4, despite topical BMD therapy (P < 0.05).
Conclusions: Topically applied BMD seems to be neuroprotective and antiapoptotic in the ET‐1‐induced ON ischaemia model, especially for RGCs. BMD might be used as an adjuvant agent for its neuroprotective effects in hypoxic‐ischaemic conditions such as diabetic retinopathy, normotensive glaucoma and other retinal vascular occlusive conditions which require further investigations.</description><identifier>ISSN: 1442-6404</identifier><identifier>EISSN: 1442-9071</identifier><identifier>DOI: 10.1111/j.1442-9071.2007.01533.x</identifier><identifier>PMID: 17760634</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject>Administration, Topical ; Adrenergic alpha-2 Receptor Agonists ; Adrenergic alpha-Agonists - administration & dosage ; Animals ; Apoptosis - drug effects ; Brimonidine Tartrate ; brimonidine tartrate 0.2 ; Cell Count ; Disease Models, Animal ; Endothelin-1 ; Infusion Pumps, Implantable ; neuroprotection ; Neuroprotective Agents - administration & dosage ; optic nerve ischaemia ; Optic Neuropathy, Ischemic - chemically induced ; Optic Neuropathy, Ischemic - pathology ; Optic Neuropathy, Ischemic - prevention & control ; Quinoxalines - administration & dosage ; Rabbits ; Retina - drug effects ; Retina - pathology ; Retinal Ganglion Cells - drug effects ; Retinal Ganglion Cells - pathology</subject><ispartof>Clinical & experimental ophthalmology, 2007-08, Vol.35 (6), p.527-534</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5023-5b91d778e11b74dc74d2ac71fd0fbab8db799ff8e60ed49f337eb2c73908b3d93</citedby><cites>FETCH-LOGICAL-c5023-5b91d778e11b74dc74d2ac71fd0fbab8db799ff8e60ed49f337eb2c73908b3d93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1442-9071.2007.01533.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1442-9071.2007.01533.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17760634$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aktas, Zeynep</creatorcontrib><creatorcontrib>Gurelik, Gokhan</creatorcontrib><creatorcontrib>Akyurek, Nalan</creatorcontrib><creatorcontrib>Onol, Merih</creatorcontrib><creatorcontrib>Hasanreisoglu, Berati</creatorcontrib><title>Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model</title><title>Clinical & experimental ophthalmology</title><addtitle>Clin Exp Ophthalmol</addtitle><description>Background: To investigate the neuroprotective effects of topically applied brimonidine tartrate 0.2% (BMD), an α2‐receptor agonist, on the retinal ganglion cell (RGC) layer and inner nuclear layer (INL) of rabbit retina in endothelin‐1 (ET‐1)‐induced optic nerve (ON) ischaemia model.
Methods: Osmotic minipumps were surgically implanted into one eye of 16 New Zealand Albino rabbits to deliver ET‐1 at the constant rate of 0.5 μL/h for 2 weeks. Eyes were divided into four groups. ET‐1 was given with (Group 3) and without topical BMD therapy (Group 1). Groups 2 and 4 were taken as controls. Rabbits were sacrificed at day 14. Morphological alterations, total cell number and proportion of cells undergoing apoptosis in INL and RGC layer were assessed by histopathological analysis to determine the survival of the cells of the INL and RGC layer.
Results: Endothelin‐1 led to severe reduction of cells in both the RGC layer and INL in Group 1 (P < 0.05). In Group 3, the total cell number and the proportion of cells undergoing apoptosis in the RGC layer were comparable with the control group (Group 4), whereas the former was found to be higher and the latter was found to be lower than those recorded for Group 1. However, the total cell number in the INL was found to be lower in Group 3 compared with that of Group 4, despite topical BMD therapy (P < 0.05).
Conclusions: Topically applied BMD seems to be neuroprotective and antiapoptotic in the ET‐1‐induced ON ischaemia model, especially for RGCs. BMD might be used as an adjuvant agent for its neuroprotective effects in hypoxic‐ischaemic conditions such as diabetic retinopathy, normotensive glaucoma and other retinal vascular occlusive conditions which require further investigations.</description><subject>Administration, Topical</subject><subject>Adrenergic alpha-2 Receptor Agonists</subject><subject>Adrenergic alpha-Agonists - administration & dosage</subject><subject>Animals</subject><subject>Apoptosis - drug effects</subject><subject>Brimonidine Tartrate</subject><subject>brimonidine tartrate 0.2</subject><subject>Cell Count</subject><subject>Disease Models, Animal</subject><subject>Endothelin-1</subject><subject>Infusion Pumps, Implantable</subject><subject>neuroprotection</subject><subject>Neuroprotective Agents - administration & dosage</subject><subject>optic nerve ischaemia</subject><subject>Optic Neuropathy, Ischemic - chemically induced</subject><subject>Optic Neuropathy, Ischemic - pathology</subject><subject>Optic Neuropathy, Ischemic - prevention & control</subject><subject>Quinoxalines - administration & dosage</subject><subject>Rabbits</subject><subject>Retina - drug effects</subject><subject>Retina - pathology</subject><subject>Retinal Ganglion Cells - drug effects</subject><subject>Retinal Ganglion Cells - pathology</subject><issn>1442-6404</issn><issn>1442-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkEtv1DAUhSMEog_4C8gb2CX4kcTxggUaSnlU7QZU1I3l2NeqhyQOtkNn_j0OMypbLFk-ks937HuKAhFckbzebitS17QUmJOKYswrTBrGqt2T4vTx4ulRtzWuT4qzGLcY44ay9nlxQjhvccvq02J_DUvwc_AJdHK_AYG1WSFvUfKz02oY9kjN8-DAoD640U_OuAlQUiEFlQDhir5GbkIwGZ_uYXBTSUo3mUVnws_JaTRByMku6nsFo1No9AaGF8Uzq4YIL4_nefH948W3zafy6uby8-b9VakbTFnZ9IIYzjsgpOe10XlTpTmxBtte9Z3puRDWdtBiMLWwjHHoqeZM4K5nRrDz4s0hNw_5a4GY5Jh_AsOgJvBLlBQLymuxGruDUQcfYwAr5zyvCntJsFxrl1u5NirXduVau_xbu9xl9NXxjaUfwfwDjz1nw7uD4cENsP_vYLm5uFlV5ssD72KC3SOvwk_ZcsYbeXt9KTcf8N3dl68_5C37A2mDokw</recordid><startdate>200708</startdate><enddate>200708</enddate><creator>Aktas, Zeynep</creator><creator>Gurelik, Gokhan</creator><creator>Akyurek, Nalan</creator><creator>Onol, Merih</creator><creator>Hasanreisoglu, Berati</creator><general>Blackwell Publishing Asia</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>200708</creationdate><title>Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model</title><author>Aktas, Zeynep ; Gurelik, Gokhan ; Akyurek, Nalan ; Onol, Merih ; Hasanreisoglu, Berati</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5023-5b91d778e11b74dc74d2ac71fd0fbab8db799ff8e60ed49f337eb2c73908b3d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Administration, Topical</topic><topic>Adrenergic alpha-2 Receptor Agonists</topic><topic>Adrenergic alpha-Agonists - administration & dosage</topic><topic>Animals</topic><topic>Apoptosis - drug effects</topic><topic>Brimonidine Tartrate</topic><topic>brimonidine tartrate 0.2</topic><topic>Cell Count</topic><topic>Disease Models, Animal</topic><topic>Endothelin-1</topic><topic>Infusion Pumps, Implantable</topic><topic>neuroprotection</topic><topic>Neuroprotective Agents - administration & dosage</topic><topic>optic nerve ischaemia</topic><topic>Optic Neuropathy, Ischemic - chemically induced</topic><topic>Optic Neuropathy, Ischemic - pathology</topic><topic>Optic Neuropathy, Ischemic - prevention & control</topic><topic>Quinoxalines - administration & dosage</topic><topic>Rabbits</topic><topic>Retina - drug effects</topic><topic>Retina - pathology</topic><topic>Retinal Ganglion Cells - drug effects</topic><topic>Retinal Ganglion Cells - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aktas, Zeynep</creatorcontrib><creatorcontrib>Gurelik, Gokhan</creatorcontrib><creatorcontrib>Akyurek, Nalan</creatorcontrib><creatorcontrib>Onol, Merih</creatorcontrib><creatorcontrib>Hasanreisoglu, Berati</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Clinical & experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aktas, Zeynep</au><au>Gurelik, Gokhan</au><au>Akyurek, Nalan</au><au>Onol, Merih</au><au>Hasanreisoglu, Berati</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model</atitle><jtitle>Clinical & experimental ophthalmology</jtitle><addtitle>Clin Exp Ophthalmol</addtitle><date>2007-08</date><risdate>2007</risdate><volume>35</volume><issue>6</issue><spage>527</spage><epage>534</epage><pages>527-534</pages><issn>1442-6404</issn><eissn>1442-9071</eissn><abstract>Background: To investigate the neuroprotective effects of topically applied brimonidine tartrate 0.2% (BMD), an α2‐receptor agonist, on the retinal ganglion cell (RGC) layer and inner nuclear layer (INL) of rabbit retina in endothelin‐1 (ET‐1)‐induced optic nerve (ON) ischaemia model.
Methods: Osmotic minipumps were surgically implanted into one eye of 16 New Zealand Albino rabbits to deliver ET‐1 at the constant rate of 0.5 μL/h for 2 weeks. Eyes were divided into four groups. ET‐1 was given with (Group 3) and without topical BMD therapy (Group 1). Groups 2 and 4 were taken as controls. Rabbits were sacrificed at day 14. Morphological alterations, total cell number and proportion of cells undergoing apoptosis in INL and RGC layer were assessed by histopathological analysis to determine the survival of the cells of the INL and RGC layer.
Results: Endothelin‐1 led to severe reduction of cells in both the RGC layer and INL in Group 1 (P < 0.05). In Group 3, the total cell number and the proportion of cells undergoing apoptosis in the RGC layer were comparable with the control group (Group 4), whereas the former was found to be higher and the latter was found to be lower than those recorded for Group 1. However, the total cell number in the INL was found to be lower in Group 3 compared with that of Group 4, despite topical BMD therapy (P < 0.05).
Conclusions: Topically applied BMD seems to be neuroprotective and antiapoptotic in the ET‐1‐induced ON ischaemia model, especially for RGCs. BMD might be used as an adjuvant agent for its neuroprotective effects in hypoxic‐ischaemic conditions such as diabetic retinopathy, normotensive glaucoma and other retinal vascular occlusive conditions which require further investigations.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>17760634</pmid><doi>10.1111/j.1442-9071.2007.01533.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1442-6404 |
| ispartof | Clinical & experimental ophthalmology, 2007-08, Vol.35 (6), p.527-534 |
| issn | 1442-6404 1442-9071 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20927499 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Topical Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists - administration & dosage Animals Apoptosis - drug effects Brimonidine Tartrate brimonidine tartrate 0.2 Cell Count Disease Models, Animal Endothelin-1 Infusion Pumps, Implantable neuroprotection Neuroprotective Agents - administration & dosage optic nerve ischaemia Optic Neuropathy, Ischemic - chemically induced Optic Neuropathy, Ischemic - pathology Optic Neuropathy, Ischemic - prevention & control Quinoxalines - administration & dosage Rabbits Retina - drug effects Retina - pathology Retinal Ganglion Cells - drug effects Retinal Ganglion Cells - pathology |
| title | Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T07%3A00%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuroprotective%20effect%20of%20topically%20applied%20brimonidine%20tartrate%200.2%25%20in%20endothelin-1-induced%20optic%20nerve%20ischaemia%20model&rft.jtitle=Clinical%20&%20experimental%20ophthalmology&rft.au=Aktas,%20Zeynep&rft.date=2007-08&rft.volume=35&rft.issue=6&rft.spage=527&rft.epage=534&rft.pages=527-534&rft.issn=1442-6404&rft.eissn=1442-9071&rft_id=info:doi/10.1111/j.1442-9071.2007.01533.x&rft_dat=%3Cproquest_cross%3E20927499%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20927499&rft_id=info:pmid/17760634&rfr_iscdi=true |